Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer

Abstract Background Nomograms are rarely employed to estimate the survival of patients with advanced and metastatic pancreatic cancer (PC). Herein, we developed a comprehensive approach to using a nomogram to predict survival probability in patients with advanced and metastatic PC. Methods: A total...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. C. Deng, Y. Lv, H. Yan, D. C. Sun, T. T. Qu, Y. T. Pan, Q. L. Han, G. H. Dai
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Nomogram Pancreatic cancer Prognosis Laboratory parameters Clinicopathological factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/12a806bf574f4d4d9e244f3fa942bfb3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:12a806bf574f4d4d9e244f3fa942bfb3
record_format	dspace
spelling	oai:doaj.org-article:12a806bf574f4d4d9e244f3fa942bfb32021-11-21T12:30:10ZNomogram to predict survival of patients with advanced and metastatic pancreatic Cancer10.1186/s12885-021-08943-w1471-2407https://doaj.org/article/12a806bf574f4d4d9e244f3fa942bfb32021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08943-whttps://doaj.org/toc/1471-2407Abstract Background Nomograms are rarely employed to estimate the survival of patients with advanced and metastatic pancreatic cancer (PC). Herein, we developed a comprehensive approach to using a nomogram to predict survival probability in patients with advanced and metastatic PC. Methods: A total of 323 patients with advanced and metastatic PC were identified from the Chinese People’s Liberation Army (PLA) General Hospital. A baseline nomogram was constructed using baseline variables of 323 patients. Additionally, 233 patients, whose tumors showed initial responses to first-line chemotherapy, were enrolled in the chemotherapy response-based model. 128 patients and 108 patients with advanced and metastatic PC from January 2019 to April 2021 were selected for external validating baseline model and chemotherapy response-based model. The 1-year and 2-year survival probability was evaluated using multivariate COX regression models. The discrimination and calibration capacity of the nomograms were assessed using C-statistic and calibration plots. The predictive accuracy and net benefit of the nomograms were evaluated using ROC curve and DCA, respectively. Results In the baseline model, six variables (gender, KPS, baseline TB, baseline N, baseline WBC and baseline CA19–9) were used in the final model. In the chemotherapy response-based model, nine variables (KPS, gender, ascites, baseline N, baseline CA 19–9, baseline CEA, change in CA 19–9 level at week, change in CEA level at week and initial response to chemotherapy) were included in the final model. The C-statistics of the baseline nomogram and the chemotherapy response-based nomogram were 0.67 (95% CI, 0.62–0.71) and 0.74 (95% CI, 0.69–0.77), respectively. Conclusion These nomograms were constructed to predict the survival probability of patients of advanced and metastatic PC. The baseline model and chemotherapy response-based model performed well in survival prediction.G. C. DengY. LvH. YanD. C. SunT. T. QuY. T. PanQ. L. HanG. H. DaiBMCarticleNomogramPancreatic cancerPrognosisLaboratory parametersClinicopathological factorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Nomogram Pancreatic cancer Prognosis Laboratory parameters Clinicopathological factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Nomogram Pancreatic cancer Prognosis Laboratory parameters Clinicopathological factors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 G. C. Deng Y. Lv H. Yan D. C. Sun T. T. Qu Y. T. Pan Q. L. Han G. H. Dai Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
description	Abstract Background Nomograms are rarely employed to estimate the survival of patients with advanced and metastatic pancreatic cancer (PC). Herein, we developed a comprehensive approach to using a nomogram to predict survival probability in patients with advanced and metastatic PC. Methods: A total of 323 patients with advanced and metastatic PC were identified from the Chinese People’s Liberation Army (PLA) General Hospital. A baseline nomogram was constructed using baseline variables of 323 patients. Additionally, 233 patients, whose tumors showed initial responses to first-line chemotherapy, were enrolled in the chemotherapy response-based model. 128 patients and 108 patients with advanced and metastatic PC from January 2019 to April 2021 were selected for external validating baseline model and chemotherapy response-based model. The 1-year and 2-year survival probability was evaluated using multivariate COX regression models. The discrimination and calibration capacity of the nomograms were assessed using C-statistic and calibration plots. The predictive accuracy and net benefit of the nomograms were evaluated using ROC curve and DCA, respectively. Results In the baseline model, six variables (gender, KPS, baseline TB, baseline N, baseline WBC and baseline CA19–9) were used in the final model. In the chemotherapy response-based model, nine variables (KPS, gender, ascites, baseline N, baseline CA 19–9, baseline CEA, change in CA 19–9 level at week, change in CEA level at week and initial response to chemotherapy) were included in the final model. The C-statistics of the baseline nomogram and the chemotherapy response-based nomogram were 0.67 (95% CI, 0.62–0.71) and 0.74 (95% CI, 0.69–0.77), respectively. Conclusion These nomograms were constructed to predict the survival probability of patients of advanced and metastatic PC. The baseline model and chemotherapy response-based model performed well in survival prediction.
format	article
author	G. C. Deng Y. Lv H. Yan D. C. Sun T. T. Qu Y. T. Pan Q. L. Han G. H. Dai
author_facet	G. C. Deng Y. Lv H. Yan D. C. Sun T. T. Qu Y. T. Pan Q. L. Han G. H. Dai
author_sort	G. C. Deng
title	Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_short	Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_full	Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_fullStr	Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_full_unstemmed	Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_sort	nomogram to predict survival of patients with advanced and metastatic pancreatic cancer
publisher	BMC
publishDate	2021
url	https://doaj.org/article/12a806bf574f4d4d9e244f3fa942bfb3
work_keys_str_mv	AT gcdeng nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT ylv nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT hyan nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT dcsun nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT ttqu nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT ytpan nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT qlhan nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer AT ghdai nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
_version_	1718418928206610432

Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer

Ejemplares similares